ROCO
4139
Market cap63mUSD
Oct 08, Last price
45.00TWD
1D
4.29%
1Q
80.72%
Jan 2017
61.64%
IPO
54.69%
Name
Ma Kuang Healthcare Holding Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Ma Kuang Healthcare Holding Limited, established in 2009 and headquartered in Kaohsiung, Taiwan, functions as an investment holding firm with a broad international and domestic presence in the healthcare sector. The company's core business involves a comprehensive range of medical services, including general community healthcare and specialized traditional Chinese medicine. Beyond direct patient care, Ma Kuang provides Chinese medicinal products, medical management training, and educational support. Its diverse offerings extend to homestay and guardianship services for overseas students, as well as a variety of consulting services encompassing corporate management, computer technology, industry information, and marketing advice. It also offers Chinese medicine beauty services and e-commerce sales. Ma Kuang manages and operates numerous facilities, such as general clinics, community medical clinics, and traditional Chinese medicine clinics, alongside educational institutions. The company further diversifies its activities through the retail sale of dietary supplements, pharmaceuticals, and medical supplies in its stores, involvement in the restaurant industry, and offering leasing and other ancillary services.
Key people
Yijun Chen
Finance Manager, Corporate Governance Officer · since 2023
Qian Yu
General Manager · since 2025
Porui Huang
Director · since 2024
Chao-wen Lee
Director · since 2025
Yunkuang Wu
Chairman of the Board · since 2025
Tsun-tsun Chang
Independent Director · since 2025
Chunwei Chen
Independent Director · since 2025
Hong-ling Shih
Independent Director · since 2025
Chong Wu
Independent Director · since 2021
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||